Answers are grounded in this paper and cite their sources.
These data demonstrate that the treatment with Empa prevents the development of renal fibrosis in Ang II-dependent hypertension. In Ang II-dependent hypertension, the anti-fibrotic effect due to SGLT2 inhibition is caused by the reduction of inflammatory infiltrates and it is independent on the modulation of blood pressure increase.
No takes yet. Share an insight, caveat, or question.
Castoldi et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: